Roche continues RNA return with $1.7B deal for Sanegene drug - Fierce Biotech
Roche continues RNA return with $1.7B deal for Sanegene drug - Fierce Biotech
Body unavailable. Use the original source.
Roche continues RNA return with $1.7B deal for Sanegene drug - Fierce Biotech
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.